Business Context and Reporting Period
This Form 8-K is filed by IMARA Inc. (not Enliven Therapeutics, Inc., as indicated in the metadata) on November 9, 2021. The filing serves to announce the Company's financial results for the quarter ended September 30, 2021, along with other business highlights. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not explicitly stated within the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that the Company announced its Q3 2021 results.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, or contingencies. It notes that the press release (Exhibit 99.1) contains the full text of the announcement and business highlights. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is IMARA Inc. (Ticker: IMRA), not Enliven Therapeutics, Inc.
- Review Exhibit 99.1 (the Press Release) for actual financial figures, as they are absent from the 8-K text.
- Confirm the reporting period is the quarter ended September 30, 2021.
- Note that the information is furnished and not deemed "filed" under Section 18 of the Exchange Act.